Sales & Marketing Just call it ‘good marketing’: Dan Gandor on why omnichannel... A Q&A with EVERSANA's new Head of Omnichannel and Digital Transformation covers omnichannel, AI, pharma marketing headwinds, and more.
News EVERSANA adds AI to medical, legal and regulatory reviews A new AI-powered solution from EVERSANA aims to take the pain out of medical, legal and regulatory (MLR) reviews.
Patients How pharma is tackling new direct-to-patient programmes At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.
Patients Direct-to-patient is more than just telehealth – with EVERSA... Hear from EVERSANA's Faruk Abdullah in this video interview as he explains why direct-to-patient strategies go beyond telehealth.
News EVERSANA joins with Veeva in push to 'pharmatise AI' EVERSANA has joined the growing roster of companies partnering with Veeva on the development of GenAI applications for the life sciences industry.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.